Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$49.86 USD
+1.93 (4.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 261 - 275 ( 275 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Note Offering Necessary To Extend Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady As She Goes; Largely Uneventful 1Q20 Report Ahead Of Mid-Year Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upgrade to Neutral; Despite Some Data Questions, Valuation Warrants Revisiting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of Detailed Data, FDA Feedback - Uneventful 4Q19 EPS Report
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
APLS Prices Secondary Offering - Extends Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PEGASUS Top-Line Meets Primary Endpoint, But More Questions Remain
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D